Last reviewed · How we verify
Olanzapine or Quetiapine or Risperidone
These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood.
These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Olanzapine or Quetiapine or Risperidone |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Olanzapine, quetiapine, and risperidone are second-generation antipsychotics that antagonize dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis. They also block serotonin 5-HT2A receptors, which contributes to their efficacy in treating both positive and negative symptoms, as well as mood stabilization in bipolar disorder.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Major depressive disorder (adjunctive treatment)
Common side effects
- Weight gain
- Sedation
- Metabolic syndrome (hyperglycemia, dyslipidemia)
- Extrapyramidal symptoms (tremor, akathisia)
- Orthostatic hypotension
- Prolactin elevation
Key clinical trials
- Enhancing Recovery in Early Schizophrenia (PHASE2)
- National Pregnancy Registry for Psychiatric Medications
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: